Se­vere ad­verse events mar the end of Roche’s PhI­II for ‘break­through’ he­mo­phil­ia drug

With Phase III da­ta loom­ing for its close­ly-watched he­mo­phil­ia drug ACE910 (emi­cizum­ab), Roche says that in­ves­ti­ga­tors have tracked four se­ri­ous cas­es of blood clot­ting among …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.